CN109091645A - 一种具有治疗hiv病毒的药物组合物 - Google Patents
一种具有治疗hiv病毒的药物组合物 Download PDFInfo
- Publication number
- CN109091645A CN109091645A CN201811286694.4A CN201811286694A CN109091645A CN 109091645 A CN109091645 A CN 109091645A CN 201811286694 A CN201811286694 A CN 201811286694A CN 109091645 A CN109091645 A CN 109091645A
- Authority
- CN
- China
- Prior art keywords
- parts
- hiv
- pharmaceutical composition
- radix
- cape jasmine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000005764 inhibitory process Effects 0.000 title claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 55
- 229940079593 drug Drugs 0.000 claims abstract description 36
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 23
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 241000207929 Scutellaria Species 0.000 claims abstract description 20
- 239000009636 Huang Qi Substances 0.000 claims abstract description 19
- 240000004980 Rheum officinale Species 0.000 claims abstract description 17
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 17
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 17
- 241000432824 Asparagus densiflorus Species 0.000 claims abstract description 16
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000126 substance Substances 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 241000245665 Taraxacum Species 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 11
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 10
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 10
- 229940116229 borneol Drugs 0.000 claims description 10
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 10
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 8
- 229960004853 betadex Drugs 0.000 claims description 8
- 235000019441 ethanol Nutrition 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000002574 poison Substances 0.000 claims description 5
- 231100000614 poison Toxicity 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 208000031886 HIV Infections Diseases 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 239000000084 colloidal system Substances 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 238000003801 milling Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000003643 water by type Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 238000000034 method Methods 0.000 abstract description 11
- 206010059866 Drug resistance Diseases 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 4
- 240000001949 Taraxacum officinale Species 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 36
- 241000282693 Cercopithecidae Species 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 210000004970 cd4 cell Anatomy 0.000 description 16
- 208000030507 AIDS Diseases 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 239000002775 capsule Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000036737 immune function Effects 0.000 description 10
- 239000008187 granular material Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000003365 immunocytochemistry Methods 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 229930186217 Glycolipid Natural products 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 235000010894 Artemisia argyi Nutrition 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 2
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 244000030166 artemisia Species 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000005096 hematological system Anatomy 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241001656831 Arctous alpina Species 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 241000510654 Bupleurum chinense Species 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000004490 capsule suspension Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 1
- 229960004253 dexmedetomidine Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- VPWFPZBFBFHIIL-UHFFFAOYSA-L disodium 4-[(4-methyl-2-sulfophenyl)diazenyl]-3-oxidonaphthalene-2-carboxylate Chemical group [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 VPWFPZBFBFHIIL-UHFFFAOYSA-L 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000027889 monkey disease Diseases 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- QLPRYZXNWYTFCI-UHFFFAOYSA-N saikosaponin D Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C2(C)CO)C(O)C(O)C1OC8OC(CO)C(O)C(O)C8O QLPRYZXNWYTFCI-UHFFFAOYSA-N 0.000 description 1
- PQPVAGWUNWFCJE-UHFFFAOYSA-N saikosaponin a Natural products CC1OC(OC2CCC3(C)C(C2)C(C)(CO)CC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C(O)C(OC8OC(CO)C(O)C(O)C8O)C1O PQPVAGWUNWFCJE-UHFFFAOYSA-N 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000007778 simian acquired immunodeficiency syndrome Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000007474 system interaction Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开一种具有治疗HIV病毒的药物组合物,它是由如下重量配比的原料药制备而成的口服制剂,大黄3—15份,黄岑3—10份,蒲公英10—15份,栀子5—15份,厚朴3—10份,天冬5—15份,柴胡3—10份,黄芪10—60份,赤芍6—12份,灵脂6—25份,砂仁5—10份。本技术方案中通过对大黄、黄岑、蒲公英、栀子、厚朴、天冬、柴胡、黄芪、赤芍、灵脂、砂仁组分、比例的合理选择和互配,增强机体的免疫力,并且降低使用过程中的毒副作用,且采用的组分均具有药食两用的功效,具有降低人体的耐药性,在治疗HIV病毒上具有良好的效果。
Description
技术领域
本发明涉及中药技术领域,具体涉及一种具有治疗HIV病毒的药物组合物。
背景技术
艾滋病是一种严重威胁人们健康的传染性其病死率极高,目前既无有效疫苗预防,又无治愈的药物,并且传播广泛,流行迅速,不但造成巨大的经济损失,还严重阻碍社会发展,已成为各国政府十分关注的社会问题。
目前AIDS的防治暂无特异性疫苗,高效抗逆转录病毒治疗(简称HAART)是目前AIDS治疗的主要方法。合理的抗病毒治疗对抑制HIV病毒的复制,提高患者的生活质量和存活率有一定作用。但西医抗病毒治疗存在以下问题:(1)不能从根本上消除HIV,即使HIV被长期抑制至血浆中不可检测的水平,HIV仍在低水平地复制;(2)HIV的抗药性及药物的不良反应:HAART临床应用4~5年后耐药性可高达70%,同时由于大多数化疗药物有较大的毒副作用,导致患者的依从性下降,25%的患者会停止HAART;(3)适应症局限:对CD4+T细胞>400/μl,血浆HIVRNA<30000的HIV感染者,不主张抗病毒治疗,而未经治疗者3年内发展至AIDS的机率>30%;(4)价格昂贵:用HAART的患者每年需要约8~10万元,目前能够自费接受HAART的患者,每年仅400~500人,我国绝大多数贫困的艾滋病患者处于无药可用的状态。
由于HAART治疗需终身服药,出于缩短用药时间考虑,治疗多是感染中后期开始,而事实上,HIV感染所形成的免疫缺陷是一个HIV病毒和免疫系统互相作用的慢性进展的过程,早、中期即出现免疫组织的进行性破坏。且目前已上市数十种抗艾滋病药物均不能治愈艾滋病,价格昂贵,容易耐药,毒副作用大,一般需要终身服药。
基于此,提供一种治疗HIV病毒的药物组合物。
发明内容
本发明针对上述问题之一,提供治疗HIV病毒的药物组合物,通过对中药组分大黄、黄岑、蒲公英、栀子、厚朴、天冬、柴胡、黄芪、赤芍、灵脂、砂仁等中药组分进行合理互配,使其发挥各自的作用,最终提高CD4数量,并维持在一个稳定的水平,解决了现有针对HIV病毒药物存在的耐药性、毒副作用大,需要终身服药等技术问题。
本发明通过下述技术方案实现:
一种具有治疗HIV病毒的药物组合物,它是由如下重量配比的原料药制备而成的口服制剂,大黄3—15份,黄岑3—10份,蒲公英10—15份,栀子5—15份,厚朴3—10份,天冬5—15份,柴胡3—10份,黄芪10—60份,赤芍6—12份,灵脂6—25份,砂仁5—10份。
进一步地,为了更好的实现本发明,所述药物组合物由如下重量配比的原料制备而成的口服制剂,大黄3份,黄岑8份,蒲公英5份,栀子8份,厚朴3份,天冬5份,柴胡3份,黄芪15份,赤芍6份,灵脂15份,砂仁8份。
进一步地,为了更好的实现本发明,所述栀子为酒炒栀子。
进一步地,为了更好的实现本发明,所述药物组合物是由所述重量配比的原料药的水或有机溶剂提取为活性成分,加上药学上常用的辅料或辅助成分而成制剂。
进一步地,为了更好的实现本发明,所述制剂为经胃肠道吸收制剂。
进一步地,为了更好的实现本发明,上述药物组合物的制备方法为:称取相应重量配比的原料药,首先将蒲公英、栀子、厚朴、天冬、柴胡、黄芪、赤芍、灵脂、砂仁、黄岑,加水煎煮,待沸腾后加入大黄,煎煮3次,每次加水5—6倍水量,每次1—1.5小时,合并滤液,滤过,滤液浓缩至45℃时,相对密度为1.20的清膏,在50—55℃下减压干燥,粉碎,采用倍他环糊精加入20%乙醇3倍量,搅拌调成糊状;另取冰片用5—8倍量95%乙醇溶解,按冰片:倍他环糊精=1:3的比例,将冰片溶液缓缓加入到上述倍他环糊精中,用胶体磨反复研磨30分钟,并逐渐调整研磨间隙至3—4um,取研磨后的糊状物,冷风吹至近干,在35—40℃的温度下干燥,粉碎制干膏细粉,即得。
进一步地,为了更好的实现本发明,所述药物组合物的用途为治疗HIV病毒的药物,能显著提高HIV患者CD4+细胞数量,提高艾滋病患者的免疫功能。
其中,CD4细胞是人体免疫系统中一种重要的免疫细胞,CD4主要表达于辅助T(Th)细胞,是Th细胞TCR识别抗原的共受体,与MHCⅡ类分子的非多肽区结合,参与Th细胞TCR识别抗原的信号转导,CD4也是HIV的受体,由于艾滋病病毒攻击对象是CD4细胞,所以其检测结果对艾滋病治疗效果的判断和对患者免疫功能的判断有着重要作用。
本技术方案所述药物组合物中,大黄苦寒实热积聚益蜀痰逐水疏通便闭,黄岑苦实、枯泻肺火,子清大肠湿热皆可,蒲公英苦溃坚消肿,结核能除,食毒堪用,栀子性寒解郁除烦,吐衄,胃痛,火降小便,厚朴苦温,消胀泄满,痰气泻痢,其功不缓,天冬甘寒,肺痿肺痈,消痰止嗽,喘热有功,柴胡味苦,能泻肝火,寒热往来,疟疾均可,黄芪性温,收汗固表,托疮生肌,气虚莫少,赤芍酸寒,能泻能散,破血通经产后勿犯,砂仁性温养胃进食,止痛安胎,行气破滞。
大黄性味苦寒,具有免疫功能的双向调节及对炎性细胞因子的抑制作用,具体为大黄对巨噬细胞免疫活性的双向调节及对血清肿瘤坏死因子-α、白细胞的抑制等重要作用和抗过敏功能。黄岑能够抑制免疫反应,尤其是对I型变态反应作用显著,黄岑能够提高机体免疫反应,黄岑含有的黄岑苷具有提高提高巨噬细胞、NK细胞的功能。蒲公英具有提高及改善小鼠细胞免疫和非特异性免疫功能的作用,对环磷酰胺所造成的小鼠免疫细胞功能损害有明显的恢复和保护作用,其有广谱的抗菌、抗病毒、抗病原微生物,提高受试机体的免疫力作用。中药栀子的熊果酸成分能通过抑制DNA的复制,阻滞细胞周期,抑制细胞的增殖,而诱导肿瘤细胞周期的终止和凋亡,另外,熊果酸还可增强机体的免疫功能,促进T、B淋巴细胞的增殖和分化,增强外周血细胞功能,减轻放射后造血细胞的损伤。中药柴胡具有抗病毒、抗炎、保肝作用,柴胡含有的柴胡皂苷-D具有抗炎、免疫抑制、免疫细胞调节作用,实验表明柴胡的提取成分对小鼠脾淋巴细胞的增殖、IL-2和肿瘤坏死因子的分泌水平均有明显的加强作用,具有较强的免疫调节作用。柴胡含有的柴胡多糖,具有提高免疫力的作用,对辐射损伤有显著的保护作用和免疫增强的作用。黄芪的主要成分黄芪多糖可显著增强非特异性免疫功能和体液免疫功能,使小白鼠吞噬绵羊红细胞百分率及指数明显增强,促进血清溶血素形成,提高空斑形成细胞的溶血功能和明显的碳离廓作用、明显增加脾重量。黄芪皂苷能促进淋巴结B细胞增殖分化和浆细胞抗体形成。黄芪能促进小鼠淋巴细胞对羊血球的免疫特异玫瑰花结的形成。黄芪多糖明显增强巨噬细胞吞噬发光强度并抑制PGE2的释放,但进一步促进TNF的释放。灵脂中含有多糖,三萜酸和真菌免疫调节蛋白等,具有抗肿瘤,降血压,降血脂,缓解神经衰弱和抗过敏等作用,是理想的保健品,故而也有“灵芝神草”之美名。
故本发明中将多味药进行合理配伍制备获得的药物组合物具有清热,健脾温肾,活血止痛及免疫调节的功能,用于辅助治疗艾滋病,改善各种并发症状,能明显提高HIV/AIDS患者的CD4+细胞数量及CD4+/CD8+比值,提高或稳定艾滋病患者的免疫功能。经多例HIV/AIDS患者的临床实验证明,病人服用本发明药物组合物后,患者感觉体力恢复、感冒次数减少、可以干活。此外还对本发明药物进行了主要药效学(猴艾滋病病毒抑制和免疫增强实验)和毒理学的基础研究,本发明实施例2的中药组合物胶囊的功效研究结果如下:
实验例1:中药组合物胶囊制剂对猴缺陷猴病毒HIV慢性感染模型质量的影响
实验对象:15岁成年猴S1、S3、S4。
针对每只猴子的用药具体过程相同,如下:
第一天上午9点给药5g,下午3点给药5g,进食、精神正常;
第二天上午9点给药5g,下午3点给药5g,进食、精神正常;
第三天上午上午9点给药5g,下午3点给药5g,进食、精神正常;
第四天上午上午9点给药5g,下午3点给药5g,进食、精神正常;
第五天开始停药。
编号S1猴子在第一天用药前的CD4细胞数量为400,第5天停药后在早晨8点,抽血检测,编号S1猴子CD4细胞计数为1100,停药16天后检测免疫细胞计数:测出编号S1猴子CD4细胞计数为1000;停药32天后检测免疫细胞计数:测出编号S1猴子CD4细胞计数为800;
编号S3猴子在第一天用药前CD4细胞数量为1500,第5天停药后早晨8点,抽血检测,编号S3猴子CD4细胞计数为2000,停药16天后检测免疫细胞计数:测出编号S3猴子CD4细胞计数为2200;停药32天后检测免疫细胞计数:测出编号S3猴子CD4细胞计数为2300;
编号S4猴子在第一天用药前CD4细胞数量为220,第5天停药后早晨8点,抽血检测,编号S4猴子CD4细胞计数为600,停药16天后检测免疫细胞计数:测出编号S4猴子CD4细胞计数为1200;停药32天后检测免疫细胞计数:测出编号S4猴子CD4细胞计数为800。
检测过程中未在编号S1、S3、S4猴子血液中检测到CD32a的抗体,检测到的抗体为总CD32分子,而CD32+C4+T细胞参与了对抗HIV病毒抗原的整个过程。
其中,编号S3猴子在用药前、第5天、停药16天后、停药32天测出的CD4细胞计数均明显高于编号S1、S4猴子,此属于猴子S4的个体差异,且编号S3猴子停药时、停药16天后、停药32天后检测出CD4的细胞计数,表示编号S3的猴子的免疫细胞数量已经逐渐恢复并稳定在正常水平范围内。
通过以上分析实验可知,所使用的中药组合物胶囊,在停药后,对免疫系统具有保护和重建作用。
实验例2:中药组合物胶囊制剂的毒理学实验研究
由于艾滋病患者需长期服药,因而药物本身的安全性也至关重要,发明人根据中药研究指导原则的方法,进行了动物急性毒性试验。
(1)急性毒性试验研究资料
急性毒性试验选用昆明种小白鼠40只,雌雄各半,体重:18±2g,给药组灌胃给予动物25%中药胶囊混悬液(中药干膏粉每克粉含生药2.001克),每日0.44ml/10g(两次给药间隔5小时),给药剂量为:31.67克生药/kg,相当于临床给药剂量704倍,对照组给等量蒸馏水。动物给药后,活动减少,安静,4小时候恢复正常,5小时候后,动物陆续有药便排出。所有动物继续正常饲养二周,动物无一死亡,且对动物进食、活动及体重增长无明显不良影响,说明该药毒性很低,按临床剂量服用安全可靠。
(2)长期毒性试验研究资料
中药胶囊大、中、小剂量组分别灌胃给予6.001g生药/kg、2.98g生药/kg和1.47g生药/kg的艾复康胶囊干膏粉,其分别相当于成人临床用量的135.4倍、61.4倍和32.7倍。一个月后一天给药两次,间隔5小时,连续给药六个月。结果显示:
1)在不同实验期间,各给药组动物白细胞及白细胞分类、红细胞及红细胞压积、血红蛋白含量、血小板、网质红细胞和全血凝血时间与空白对照组比较均无显著差异,且均在正常范围内,提示艾复康胶囊长期服用对血液系统无明显不良影响。
2)给药三个月、六个月及恢复期所有动物血液生化检查未见明显不良反应。给药大、中、小剂量组动物肝肾功能及糖脂代谢与空白对照组比较也未见不良影响,提示中药胶囊对肝肾功能及糖脂代谢无明显不良影响。
3)给药三个月时,给药各剂量组动物肝和肾脏器指数较明显高于空白对照组,由于药物主要在肝脏代谢,本实验给药剂量很大,可能刺激肝脏代偿性的生长;大鼠主要脏器的脏器系数与对照组比较无显著差异;对心、主动脉、肺、气管、肝、脾、肾、膀胱、胸腺、肠系膜淋巴结、食管、胃、十二指肠、回肠、结肠、胰腺、唾液腺、垂体、甲状腺、甲状旁腺、肾上腺、脑、脊髓、视神经、坐骨神经、睾丸、附睾、前列腺、卵巢、子宫、乳腺等脏器进行病理检查,均为见由药物引起的病理形态学损伤。
中药胶囊长期给药对动物外观体征、行为活动、体重增长、进食以及各主要脏器组织等未见明显不良影响;血液学常规检查及血液生化检查结果显示,该药对血液系统、肝肾功能及糖脂代谢无明显不良影响。
本发明与现有技术相比,具有如下的优点和有益效果:
(1)本技术方案中通过对大黄、黄岑、蒲公英、栀子、厚朴、天冬、柴胡、黄芪、赤芍、灵脂、砂仁组分、比例的合理选择和互配,增强机体的免疫力,并且降低使用过程中的毒副作用,且采用的组分均具有药食两用的功效,具有降低人体的耐药性,在治疗HIV病毒上具有良好的效果。
(2)本发明主要针对艾滋病对耐药珠,主要针对核酸、多肽、鸡尾酒耐药病人,与以往抗病毒药物不同是可有效的保护CD4细胞增强人体免疫系统,使细胞传递抗病毒能力,从而抑制病毒生成使与病毒共生存的新概念,而且可以停病以后终身不用服药。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明白,下面结合实施例,对本发明作进一步的详细说明,本发明的示意性实施方式及其说明仅用于解释本发明,并不作为对本发明的限定。
实施例1:
中药组合物提取物的制备,所述药物组合物由如下重量配比的原料制备而成的口服制剂,大黄3份,黄岑8份,蒲公英5份,栀子8份,厚朴3份,天冬5份,柴胡3份,黄芪15份,赤芍6份,灵脂15份,砂仁8份。
其中,所述栀子为酒炒栀子。
称取上述相应重量配比的原料药,首先将蒲公英、栀子、厚朴、天冬、柴胡、黄芪、赤芍、灵脂、砂仁、黄岑,加水煎煮,待沸腾后加入大黄,煎煮3次,每次加水5倍水量,每次1小时,合并滤液,滤过,滤液浓缩至45℃时,相对密度为1.20的清膏,在50℃下减压干燥,粉碎,采用倍他环糊精加入20%乙醇3倍量,搅拌调成糊状;另取冰片用5倍量95%乙醇溶解,按冰片:倍他环糊精=1:3的比例,将冰片溶液缓缓加入到上述倍他环糊精中,用胶体磨反复研磨30分钟,并逐渐调整研磨间隙至3um,取研磨后的糊状物,冷风吹至近干,在35℃的温度下干燥,粉碎制干膏细粉,即得。
实施例2:
中药组合物颗粒剂的制备,
中药组合物,是由如下重量配比的原料药制备而成的口服制剂,大黄3份,黄岑3份,蒲公英10份,栀子5份,厚朴3份,天冬5份,柴胡3份,黄芪10份,赤芍6份,灵脂6份,砂仁5份。
称取相应重量配比的原料药,首先将蒲公英、栀子、厚朴、天冬、柴胡、黄芪、赤芍、灵脂、砂仁、黄岑,加水煎煮,待沸腾后加入大黄,煎煮3次,每次加水6倍水量,每次1.5小时,合并滤液,滤过,滤液浓缩至45℃时,相对密度为1.20的清膏,在55℃下减压干燥,粉碎,采用倍他环糊精加入20%乙醇3倍量,搅拌调成糊状;另取冰片用8倍量95%乙醇溶解,按冰片:倍他环糊精=1:3的比例,将冰片溶液缓缓加入到上述倍他环糊精中,用胶体磨反复研磨30分钟,并逐渐调整研磨间隙至4um,取研磨后的糊状物,冷风吹至近干,在40℃的温度下干燥,粉碎制干膏细粉,混匀,制成颗粒,60℃以下干燥,40目过筛整粒度,即得颗粒剂。
实施例3:
中药组合物胶囊剂的制备,将实施例2所述颗粒剂装入胶囊,按照常规胶囊剂制备工艺制备成胶囊剂,其中干膏粉每克粉含生药1.467g。
且本实施例中选择的中药组合物,它是由如下重量配比的原料药制备而成的口服制剂,大黄15份,黄岑10份,蒲公英15份,栀子15份,厚朴10份,天冬15份,柴胡10份,黄芪60份,赤芍12份,灵脂25份,砂仁10份。
其余与实施例2相同。
实施例4:
中药组合物口服液的制备,取实施例1所述的中药提取物,用水溶解成溶液,过滤,灌装,加盖,115℃30分钟灭菌,贴签,制成口服液。
实施例5:采用实施例2制备获得的颗粒剂应用于HIV病毒的治疗,具体治疗方式如下:
薛某,男,60岁,在2017年4月检测HIV呈阳性,服用拉米夫定后出现过敏症状,然后服用克立芒仍然出现过敏症状,并从2018年5月到2018年6月开始服用本中药组合物,每日服用两次,每次2—3颗,每颗相当于主药成分2—3g,连续服药一个月后,提取血液样本,采用检测仪器NAVIOS进行检测,结果如下:
首先,下表为薛某服用本药物之前的检测结果:
以采集血液作为样本,采用荧光定量PCR方法,检测病毒载量指标,
检验项目 | 项目名称 | 结果 | 单位 | 检测下限 |
HIV | HIV-1病毒载量 | 105219 | Copies/ml | 40—10000000 |
用药前检测结果表示:CD4+/CD8+比值小于1,此时病人已感染HIV病毒。
薛某用药至6月,提取血液样本,采用检测仪器NAVIOS进行检测,结果如下:
薛某停药至9月,提取全血作为样本,采用检测仪器检测结果如下:
其中CD4+(又称CD4)是人体免疫系统中一种重要的免疫细胞,CD4主要表达于辅助T细胞,是Th细胞TCR细胞识别抗原的共受体,与MHCⅡ类分子的非多肽区结合,参与Th细胞TCR识别抗原的信号转导。CD4也是HIV的受体,由于艾滋病病毒攻击对象是CD4细胞,所以其检测结果对艾滋病治疗效果的判断和对患者免疫功能的判断有着重要作用。
CD8(又称CD8+)为细胞毒性T细胞,可以消灭受感染的细胞,这也包括受HIV病毒感染的CD4细胞。正常情况下,未感染HIV病毒的人体,两者的比值通常是大于1的。通过上述检测结果可知,服用本发明所述颗粒剂,停药至9月检测结果可知,CD4+/CD8+比值大于1,血浆中病毒载药量小于10000000,则HIV病毒已经被杀死,血液内无HIV病毒,对治疗HIV病毒有显著效果,且各项检测指标稳定到相对平衡的水平。
实施例6:
采用实施例2制备获得的颗粒剂应用于HIV病毒的治疗,具体治疗方式如下:
王某,男,55岁,在2018年5月检测HIV呈阳性,开始服用拉米夫定,依夫韦伦和A2T,服用后出现过敏症状,然后从2018年5月到2018年6月开始服用本中药组合物,每日服用两次,每次2—3颗,每颗相当于主药成分2—3g,连续服药一个月后,提取血液样本,采用检测仪器NAVIOS进行检测:
王某在服药前,提取血液样本,检测结果如下:
以采集血液作为样本,采用荧光定量PCR方法,检测病毒载量指标,
检验项目 | 项目名称 | 结果 | 单位 | 检测下限 |
HIV | HIV-1病毒载量 | 1542 | Copies/ml | 40—10000000 |
用药前检测结果表示:CD4+/CD8+比值小于1,此时病人已感染HIV病毒。
王某用药至6月,提取血液样本,采用检测仪器NAVIOS进行检测,结果如下:
王某停药至9月,提取全血作为样本,采用检测仪器检测结果如下:
通过上述检测结果可知,服用本发明所述颗粒剂,在9月检测时,CD4+/CD8+比值大于1,血浆中病毒载药量小于10000000,可知,HIV病毒已经被杀死,血液内无HIV病毒,对治疗HIV病毒有很好的治疗效果,且各项检测指标稳定到相对稳定水平。
患者王某、薛某在服用本实施例所述药物之前服用富咪定,右美托咪定等抗HIV药物时均出现呕吐、眩晕等不良反应且产生耐药性,而服用本发明所述中药颗粒时未出现相应的不良反应、耐药性的情况。
以上所述的具体实施方式,对本发明的目的、技术方案和有益效果进行了进一步详细说明,所应理解的是,以上所述仅为本发明的具体实施方式而已,并不用于限定本发明的保护范围,凡在本发明的精神和原则之内,所做的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (8)
1.一种具有治疗HIV病毒的药物组合物,其特征在于:它是由如下重量配比的原料药制备而成的口服制剂,大黄3—15份,黄岑3—10份,蒲公英10—15份,栀子5—15份,厚朴3—10份,天冬5—15份,柴胡3—10份,黄芪10—60份,赤芍6—12份,灵脂6—25份,砂仁5—10份。
2.根据权利要求1所述的一种具有治疗HIV病毒的药物组合物,其特征在于:所述药物组合物由如下重量配比的原料制备而成的口服制剂,大黄3份,黄岑8份,蒲公英5份,栀子8份,厚朴3份,天冬5份,柴胡3份,黄芪15份,赤芍6份,灵脂15份,砂仁8份。
3.根据权利要求2所述的一种具有治疗HIV病毒的药物组合物,其特征在于:所述栀子为酒炒栀子。
4.根据权利要求1所述的一种具有治疗HIV病毒的药物组合物,其特征在于:所述药物组合物是由所述重量配比的原料药的水或有机溶剂提取为活性成分,加上药学上常用的辅料或辅助成分而成制剂。
5.根据权利要求4所述的一种具有治疗HIV病毒的药物组合物,其特征在于:所述制剂为经胃肠道吸收制剂。
6.根据权利要求1-5任意一项所述药物组合物的制备方法,其特征在于:将以上药物研磨成粉末,调服或煎服。
7.根据权利要求1-5任意一项所述药物组合物的制备方法,其特征在于:称取相应重量配比的原料药,首先将蒲公英、栀子、厚朴、天冬、柴胡、黄芪、赤芍、灵脂、砂仁、黄岑,加水煎煮,待沸腾后加入大黄,煎煮3次,每次加水5—6倍水量,每次1—1.5小时,合并滤液,滤过,滤液浓缩至45℃时,相对密度为1.20的清膏,在50—55℃下减压干燥,粉碎,采用倍他环糊精加入20%乙醇3倍量,搅拌调成糊状;另取冰片用5—8倍量95%乙醇溶解,按冰片:倍他环糊精=1:3的比例,将冰片溶液缓缓加入到上述倍他环糊精糊状物中,用胶体磨反复研磨30分钟,并逐渐调整研磨间隙至3—4um,取研磨后的糊状物,冷风吹至近干,在35—40℃的温度下干燥,粉碎制干膏细粉,即得。
8.根据权利要求1—5所述药物组合物的用途,其特征在于:所述药物组合物治疗HIV病毒的药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811286694.4A CN109091645A (zh) | 2018-10-31 | 2018-10-31 | 一种具有治疗hiv病毒的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811286694.4A CN109091645A (zh) | 2018-10-31 | 2018-10-31 | 一种具有治疗hiv病毒的药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109091645A true CN109091645A (zh) | 2018-12-28 |
Family
ID=64869916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811286694.4A Pending CN109091645A (zh) | 2018-10-31 | 2018-10-31 | 一种具有治疗hiv病毒的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109091645A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110755601A (zh) * | 2019-10-31 | 2020-02-07 | 云南康洲生物科技有限公司 | 一种治疗hiv/aids免疫重建缺陷的芸豆凝集素植物药组合物和制备方法及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1803163A (zh) * | 2005-06-16 | 2006-07-19 | 哈尔滨市高新生物技术应用研究所 | 一种治疗艾滋病的中药 |
US20080118582A1 (en) * | 2006-11-16 | 2008-05-22 | Jose Angel Olalde Rangel | Synergistic Inmune Phyto-Nutraceutical Composition |
CN101700321A (zh) * | 2009-11-19 | 2010-05-05 | 南通艾奇康药业科技有限公司 | 一种治疗艾滋病的中药组合物及其制备方法 |
CN102908443A (zh) * | 2012-11-15 | 2013-02-06 | 宋福德 | 一种治疗或辅助治疗艾滋病的药物组合物及其制备方法和用途 |
CN107569564A (zh) * | 2017-09-14 | 2018-01-12 | 桂林医学院 | 一种艾滋病辅助治疗药物及其制备方法 |
-
2018
- 2018-10-31 CN CN201811286694.4A patent/CN109091645A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1803163A (zh) * | 2005-06-16 | 2006-07-19 | 哈尔滨市高新生物技术应用研究所 | 一种治疗艾滋病的中药 |
US20080118582A1 (en) * | 2006-11-16 | 2008-05-22 | Jose Angel Olalde Rangel | Synergistic Inmune Phyto-Nutraceutical Composition |
CN101700321A (zh) * | 2009-11-19 | 2010-05-05 | 南通艾奇康药业科技有限公司 | 一种治疗艾滋病的中药组合物及其制备方法 |
CN102908443A (zh) * | 2012-11-15 | 2013-02-06 | 宋福德 | 一种治疗或辅助治疗艾滋病的药物组合物及其制备方法和用途 |
CN107569564A (zh) * | 2017-09-14 | 2018-01-12 | 桂林医学院 | 一种艾滋病辅助治疗药物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
王占玺: "《中药处方的应用》", 30 April 1980, 科学技术文献出版社 * |
王明三、王长民: "《《疑难病症中医辨证与综合治疗》》", 31 July 1994, 山东大学出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110755601A (zh) * | 2019-10-31 | 2020-02-07 | 云南康洲生物科技有限公司 | 一种治疗hiv/aids免疫重建缺陷的芸豆凝集素植物药组合物和制备方法及其应用 |
CN110755601B (zh) * | 2019-10-31 | 2023-06-23 | 云南康洲生物科技有限公司 | 一种治疗hiv/aids免疫重建缺陷的芸豆凝集素植物药组合物和制备方法及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103239549B (zh) | 一种抗超级细菌ndm-1耐药基因细菌的中药组合物 | |
CN102940779A (zh) | 一种治疗慢性溃疡性结肠炎的药物组合物及其制备方法 | |
CN101254261A (zh) | 一种具有催眠、抗抑郁、抗焦虑作用的药物组合物及其制备方法 | |
CN1935194B (zh) | 一种治疗肾病的中药组合物的制备方法 | |
CN102657736B (zh) | 一种治疗类风湿性关节炎的药物组合物及其制备方法 | |
CN111214637A (zh) | 一种中药组合物及其制备方法和药用用途 | |
CN109091645A (zh) | 一种具有治疗hiv病毒的药物组合物 | |
CN102908443B (zh) | 一种治疗或辅助治疗艾滋病的药物组合物及其制备方法和用途 | |
CN106309729B (zh) | 一种调节慢性肝炎免疫功能的中药组合物 | |
CN101810671B (zh) | 一种治疗艾滋病的中药制剂及其制备方法 | |
CN1814217B (zh) | 一种治疗风湿关节炎的中药组合物及其制备方法 | |
CN1326551C (zh) | 一种用于辅助治疗恶性肿瘤的制剂及其制备方法 | |
CN102805810B (zh) | 一种治疗艾滋病的中药制剂及相应的制备方法 | |
CN102631498B (zh) | 中药组合物 | |
CN100581566C (zh) | 一种治疗心律失常的中药制剂 | |
Siddiqui et al. | The effects of new polyherbal Unani formulation AJMAL06 on serum creatinine level in chronic renal failure | |
CN1943658B (zh) | 一种治疗急慢性肝炎的中药组合物及其制备方法 | |
CN107823487B (zh) | 一种治疗非酒精性脂肪肝的中药组合物及其制备方法与应用 | |
CN108635457A (zh) | 一种治疗便秘的中药组合物及其制备方法与应用 | |
CN102805795B (zh) | 一种治疗急性胸胁部软组织损伤的中药组合物及其应用 | |
CN102488851A (zh) | 治疗反复发作生殖器疱疹的药物及其制备方法 | |
CN101991730A (zh) | 一种治疗支气管哮喘抗复发的中药复方制剂及其制备方法 | |
CN100998785B (zh) | 一种治疗胃肠疾病的中药组合物及其制备方法 | |
CN1814193B (zh) | 一种治疗肾炎水肿的中药组合物及其制备方法 | |
CN107233540A (zh) | 一种治疗类风湿关节炎的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181228 |